Back to News
Market Impact: 0.1
Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors
Source: GlobeNewswire
Healthcare & BiotechManagement & Governance
The article fragment describes an individual with more than 25 years of experience in clinical strategy, biostatistics and regulatory submissions at Abivax, Alumis, MyoKardia and Genentech/Roche. It provides no role, company announcement or financial impact details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- Roche Gets FDA Approval for Another Label Expansion of Tecentriq
- ‘I drive a Tesla’: After Elon Musk said he’d lose his job, Delta CEO Ed Bastian says there’s ‘no tit for tat’ as airline unveils earnings miss
- Trump created a committee to dig into the Fed's Lisa Cook. What is it and what comes next?
- ‘Indentured servants’: US green card move will hit thousands of IT workers
- Teva wins FDA approval for monthly schizophrenia injection Weltruza
- BofA downgrades Alignment Healthcare stock rating on star rating drop
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Live Event Center, In-App Documents, and Faster Transcripts
- How to Automate Equity Research Workflows: A Control-First Guide